Hypertrophic CARdiomyopathy symptom release by alpha stimulant MIDOdrine - Light-CARMIDO

CHU de Bordeaux0 个研究点开始时间: 2015年9月8日最近更新: 2015年12月7日

适应症

试验速览

暂无简介。

•- Adults aged 18-80 years of both sexes,
•- Patients carrying a typical or atypical hypertrophic cardiomyopathy diagnosed by cardiac imaging (echocardiography and MRI) and / or genetic testing or family history,
•- Obstruction per-effort treadmill (in aortic obstruction> 50 mmHg measured continuously aligned with the Doppler aortic ejection)
•- Positive response (<50 mmHg obstruction) test Leg-lifting of rest and / or immediate post-exercise
•- Symptomatic to stress in daily life: dyspnea NYHA 2-3, non coronary chest pain, fainting effort,
•- Exploitable ultrasonic window,
•- Sinus rhythm,
•- Optimal medical treatment,
•- For women of childbearing potential, effective contraception and required negative pregnancy test,
•- Intent Consent form signed by the patient after having read the information letter,
•- Patient affiliated to national health system.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 40

•- Minor Patient,
•- Taking Gutron® earlier,
•- Extra-cardiac pathology limiting life expectancy to less than a year,
•- Inability to consent or refusal to sign the consent,
•- Pregnant and breastfeeding women,
•- Hypertrophy secondary to hypertensive or valvular disease,
•- Permanent atrial fibrillation,
•- Threatening ventricular rhythm disorders (ventricular doublets, bigeminy, bursts TV) without a pacemaker,
•- Severe Coronary Artery Disease,
•- Hypertension unbalanced by the usual therapeutic,
•- Severe heart disease (Fe <40% or severe elevated filling pressures, pulmonary hypertension> 60 mmHg)
•- Narrow Angle Glaucoma,
•- Obliterative vasculopathy severe,
•- Vasospasm,
•- Thyrotoxicosis,
•- Pheochromocytoma,
•- Severe renal impairment <30ml / min,
•- Raynaud's disease,
•- History of CHD pain,
•- Non-selective MAO inhibitors (iproniazid, nialamide) or indirect sympathomimetic (ephedrine, methylphenidate, phenylephrine, pseudoephedrine), or digitalis,
•- Any procedure modifying the venous return: vein stripping / venotomy the lower limbs,
•- Participation in another biomedical research study,
•- Criteria relating to the regulation: persons under safeguard justice, physical and / or psychological severely impaired, which according to the investigator, may affect the compliance of participating in the study

发起方

CHU de Bordeaux